Greenwich LifeSciences, Inc.
NASDAQ:GLSIBiotechnology
-$0.74 today
- Market cap
- $290.48M
- Beta
- 1.38
- P/E (TTM)
- -15.6
- EPS (TTM)
- -$1.49
Volume 0.23M
Average 0.14M
Returns on capital
Greenwich LifeSciences, Inc. management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
-1081.2%
avg -188.4%
ROIC
154.8%
avg 31.4%
ROA
287.3%
avg -2283.5%
Analysis
ROA is currently the strongest return metric at 287.3% versus its period average of -2283.5%. 2 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
Snehal S. Patel | Chief Executive Officer, Chief Financial Officer & Director | USD 1.1M | 62 | — | — |
Eric Rothe | Founder & Independent Director | USD 65.64K | 51 | 82.70K | 0.56% |
Christine T. Fischette | Vice President of Business Development | — | 75 | — | — |
Frank Joseph Daugherty | Chief Medical Officer & Director | — | 76 | 209.78K | 1.43% |
Jaye L. Thompson | Vice President Clinical & Regulatory Affairs | — | 60 | — | — |
Compensation is shown in the reported currency; data updated Nov 7, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Dec 24, 2024.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
11
$475,672.00
Sells
0
$0.00
Net Transaction Value
+$475,672.00
Net buying
Most Active
Patel Snehal
11 transactions
Transactions sorted by date, descending.
| Type | |||
|---|---|---|---|
| Jul 29, 26Jul 29, 2026 | Patel Snehal Direct | Buy | $9.2K$9,170.00 |
| Jul 28, 26Jul 28, 2026 | Patel Snehal Direct | Buy | $20.4K$20,385.00 |
| Jul 27, 26Jul 27, 2026 | Patel Snehal Direct | Buy | $20.4K$20,430.00 |
| Jul 24, 26Jul 24, 2026 | Patel Snehal Direct | Buy | $14.2K$14,168.00 |
| Jul 23, 26Jul 23, 2026 | Patel Snehal Direct | Buy | $32.9K$32,850.00 |
| Jan 13, 26Jan 13, 2026 | Patel Snehal Direct | Buy | $53.7K$53,694.00 |
| Jan 12, 26Jan 12, 2026 | Patel Snehal Direct | Buy | $79.9K$79,866.00 |
| Dec 31, 25Dec 31, 2025 | Patel Snehal Direct | Buy | $91.8K$91,848.00 |
| Dec 30, 25Dec 30, 2025 | Patel Snehal Direct | Buy | $63K$63,017.00 |
| Dec 18, 25Dec 18, 2025 | Patel Snehal Direct | Buy | $51.7K$51,742.00 |
1–10 of 11
Summary
Insiders reported 11 buys worth $475,672.00 and 0 sells worth $0.00 over the last 12 months. That adds up to net buying of $475,672.00. Patel Snehal was the most active insider with 11 transactions.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | N/A | N/A1 analysts |
| Net Income | N/A | N/A | N/A | N/A1 analysts |
| EBIT | N/A | N/A | N/A | N/A1 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Who does Greenwich LifeSciences, Inc. compete with?
Open similar companies to compare how their management teams allocate capital.
Questions
Management questions
Common questions about GLSI's management, answered from reported figures.
Who manages GLSI?
Greenwich LifeSciences, Inc. (GLSI) lists 5 active executives. The top listed executive is Christine T. Fischette, Vice President of Business Development.
Are GLSI insiders buying or selling?
Recent insider activity shows net buying of $29.05M.
Continue the stock analysis
Jump to another research area for this company.